Market Overview
The global heparin market is expected to grow at a CAGR in the forecast period (2021-2028).

Heparin prevents blood clot formation within the blood vessels and is used to treat heart conditions and unstable angina. It is also used in post-surgery, dialysis, and transfusion of blood. Heparin is usually injected into the muscle or veins directly to break up clots and maintain smooth blood fluidity. The heparin market can be divided based on its types as low molecular weight heparin, ultra-low molecular weight heparin, and unfractionated heparin. This heparin market research report analyzes the market’s competitive landscape and offers information on several market vendors.

Download free sample: https://www.datamintelligence.com/download-sample/heparin-market

Market Dynamics

The primary factor for the growth of the heparin market is the growing burden of chronic diseases.

According to the World Health Organization, chronic diseases have always been a massive global challenge, and they account for approximately 60% of all deaths worldwide. The global burden of chronic diseases was expected to reach 57% by 2020. Furthermore, according to the Organization for Economic Co-operation and Development (OECD), Health at a Glance, 2019 report, almost one-third of people aged 15 years and over reported living with two or more chronic conditions, which include cancer, heart attack and stroke, chronic respiratory problems, and diabetes, on average across 27 OECD countries globally.

Growing potential applications of Heparin can drive market growth tremendously

Heparin acts as an anticoagulant that prevents the formation of blood clots, so it is used before surgery to reduce the risk of blood clot in the veins, arteries, or lungs. As a result, the demand for heparin has increased.The rising prevalence of various medical ailments such as deep vein thrombosis (DVT) and pulmonary embolism (PE) is one of the key factors driving the global market. Also, heparin has been proven to be an extremely effective drug for venous thromboembolism and cardiovascular disorders (CVDs), which is contributing significantly to its market growth.

Furthermore, biopharmaceutical companies are developing innovative medicines to enhance the therapeutic potential of heparin and reduce its side-effects. Availability of synthetic and semi-synthetic heparin mimetics that assist in treating various cancers, coagulation and inflammatory diseases is significantly increasing the adoption of the product.

Market Segmentation

Global Heparin Market – By Product Type

  • Low Molecular Weight Heparin (LMWH)*
  • Ultra-low Molecular Weight Heparin (ULMWH)
  • Unfractionated Heparin

Global Heparin Market – By Source Type

  • Bovine
  • Porcine

Global Heparin Market – By Formulation Type

  • Oral
  • Parenteral

Global Heparin Market – By Application

  • Deep Vein Thrombosis
  • Pulmonary Embolism
  • Arterial Embolism
  • Others

Global Heparin Market – By End-User

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers
  • Others

Global Heparin Market – By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

View full report: https://www.datamintelligence.com/research-report/heparin-market

Competitive Landscape

The heparin market is moderately competitive with presence of local as well as global companies.  The report presents a detailed analysis of the following key players in the global heparin market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions. The key players are Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co. KGaA, Sanofi, Pfizer, Inc., LEO Pharma A/S, Aspen, Baxter International Inc., B. Braun Melsungen AG, and Syntex S.A.

Trending Topics

Rare Haematology Market

Dyslipidemia Market

Antithrombin Market

Blood Plasma Derivatives Market

Allogeneic Stem Cells Market

Tags: Pfizer, Bovine, Deep Vein Thrombosis, Porcine, Heparin, Heparin Market, Aspen, Pulmonary Embolism, Sanofi, B. Braun Melsungen AG, Arterial Embolism, Syntex S.A, Baxter International Inc, LEO Pharma, Teva Pharmaceutical Industries, Dr. Reddy’s Laboratories Ltd

See Campaign: https://www.datamintelligence.com/research-report/heparin-market
Contact Information:
Sai Kiran Sales Manager at DataM Intelligence Email: [email protected] Tel: +1 877 441 4866 Website: www.datamintelligence.com

Tags:
Menafn, Reportedtimes, PR-Wirein, Extended Distribution, iCN Internal Distribution, Research Newswire, English